Hoth Therapeutics, Inc. (HOTH) Analysis

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a primary endpoint achievement, a clinical site addition and additional development candidate data. COMPASS PATHWAYS ACHIEVES PRIMARY ENDPOINT IN COMP360 TRIAL: Compass Pathways (CMPS) announced Monday the achievement of the primary endpoint in the ongoing Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, fo

For anyone who read my due diligence on HOTH here: https://www.reddit.com/r/pennystocks/s/OgU6HaPCXG You’ll be interested to know that there is another live interview with the CEO tomorrow on YouTube. Here is the link. https://www.youtube.com/live/KhFa2QsjHkI?si=n05XjixRIWds8XBH We’re expecting positive news on the pipeline of products and potential FDA approval.